ACE2 News and Research

RSS

Study shows COVID-19 vulnerability is highly dependent on host genetic architecture

A new US study available on the preprint server medRxiv reveals certain genetic variations that are associated with infection susceptibility and diverse clinical presentation of coronavirus disease (COVID-19) – including asymptomatic cases and severe forms of the disease in younger patients.

10 May 2020

ACE inhibitors should not be discontinued over fears about COVID-19, say researchers

Researchers in Europe have found no evidence to support previous reports that the use of drugs that target the renin-angiotensin-aldosterone system (RAAS) increases susceptibility to coronavirus disease 2019 (COVID-19). The research is published in the European Heart Journal.

10 May 2020

Repurposing existing drugs is a more rapid alternative than developing COVID-19 vaccine

Repurposing existing medicines focused on known drug targets is likely to offer a more rapid hope of tackling COVID-19 than developing and manufacturing a vaccine, argue an international team of scientists in the British Journal of Pharmacology today.

8 May 2020

Predicting the dose for repurposing nitazoxanide in COVID-19

A new study published on the preprint server medRxiv in May 2020 reports a model that could help evolve appropriate dosage protocols for future clinical trials of the repurposed drug nitazoxanide in COVID-19 prevention and treatment. The researchers say, “It was possible to achieve plasma and lung tizoxanide concentrations, using proven safe doses of nitazoxanide, that exceed the EC90 for SARS-CoV-2.”

7 May 2020

Twist Bioscience Identifies Competitive Antibodies for SARS-CoV-2

Twist Bioscience Corporation has identified competitive antibodies to SARS-CoV-2, which could potentially be used for diagnostic tests and treatments.

7 May 2020

Study discovers inhibition of SARS-CoV-2 entry priming protein by approved drug

The COVID-19 pandemic caused by the severe acute respiratory syndrome -coronavirus 2 (SARS-CoV-2) has spread to most of the world, causing millions of cases and hundreds of thousands of deaths. A new study published on the preprint server bioRxiv* shows that a protease inhibitor drug already approved by the Food and Drug Administration (FDA) could inhibit viral entry.

6 May 2020

Low CD8 and NK cell counts in the lung linked to high SARS-CoV-2 ACE2 receptor levels

A new study published on the preprint server bioRxiv in April 2020 reports that low levels of specific immune cells, namely, CD8 T cells and NK cells, are linked to higher expression of the ACE2 molecule, which acts as a receptor for the CoV.

6 May 2020

Is ACEI, ARB use linked to testing positive for COVID-19?

A new study published in the prestigious journal JAMA Cardiology in May 2020 reports that there is no association between the use of ACEIs/ARBs and testing positive for COVID-19. This supports current medical advice to continue using these drugs as indicated irrespective of the ongoing pandemic but indicates the need for more research to rule out any additional risk of severe illness due to these agents.

6 May 2020

SARS-CoV-2 genome shows mutation hotspots and type-specific distribution

Now, a new study published on the preprint server bioRxiv reports on a large scale analysis of SARS-CoV-2 genomes and reveals a clonal geo-distribution and rich genetic variations.

5 May 2020

COVID-19 infection risk and outcomes explained by the cell receptor genetic variability

Genetic variants in the angiotensin‐converting enzyme 2 (ACE2) receptor, utilized by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) for cell entry, are predicted to either encourage or inhibit interaction with viral proteins and subsequently contribute to genetic risk in coronavirus disease (COVID-19). This is the key finding of a new study available on the preprint server bioRxiv*.

5 May 2020

Russian scientists create humanized mice to test drugs and vaccines for COVID-19

Following the recent Coronavirus outbreak, almost three million people have been infected worldwide, whereas the death toll has already passed the 200,000 mark, according to official reports.

5 May 2020

Loss of smell may be related to neuroinvasive propensity of SARS-CoV-2

The novel coronavirus has rapidly infected millions over the world in over 187 countries and territories, causing hundreds of thousands of deaths. One of the often-neglected and under-reported symptoms of the virus is the loss of the sense of smell or anosmia. Now, a new study out of Germany published on the preprint server medRxiv in April 2020 provides a quantified estimate of the magnitude of anosmia as a symptom of the coronavirus.

4 May 2020

SARS-CoV-2 receptor ‘mimic' could prevent COVID-19

Researchers from Italy have developed an exciting new peptide drug that could potentially prevent the coronavirus from infecting people’s cells. The paper, published on the preprint server bioRxiv* in April 2020, describes a small molecule that can bind to and block the attachment site on the virus spike protein, preventing its entry into the host cell.

4 May 2020

Research detects a more dangerous SARS-CoV-2 mutation

A new study published on the preprint server bioRxiv in May 2020 reports the setting up of a system to help track new mutations in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that is behind the current COVID-19 pandemic. This will help analyze mutations to find and track the spread of those that are most likely to increase the pathogenicity of the virus, either by making it easier to transmit or by enhancing its resistance to treatment.

4 May 2020

High blood pressure drugs found to be safe for COVID-19 patients

Despite concerns expressed by some experts, common high blood pressure drugs did not increase the risk of contracting COVID-19 - or of developing severe disease - in a study of 12,594 patients.

3 May 2020

Spike protein analysis from India's first SARS-CoV-2

A new study published on the preprint server bioRxiv analyzes viral spike protein sequences from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak in West Bengal, India, comparing them with sequences from other Indian states and Wuhan, China.

30 Apr 2020

New clinical trial to assess whether hypertension drug may reduce COVID-19 severity

Researchers at University of California San Diego School of Medicine have launched a clinical trial to investigate whether a drug approved for treating high blood pressure, heart failure and diabetic kidney disease might also reduce the severity of COVID-19 infections, lowering rates for intensive care unit admissions, the use of mechanical ventilators and all-cause mortality.

30 Apr 2020

New database catalogs peptides that may halt SARS-CoV-2 cell infection

In the quest for a highly specific and tailored treatment strategy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a recent publication available on the preprint server bioRxiv describes a repository of designed peptides that interfere with the early stages of viral invasion process.

30 Apr 2020

Tobacco smoking identified as a potential risk factor for COVID-19 infection

Researchers at Baylor College of Medicine, the University of South Carolina and other institutions have identified tobacco smoking as a potential risk factor for infection of the COVID-19 virus.

29 Apr 2020

Radboudumc researchers find essential mechanism in the disease process of COVID-19

Researchers at the Radboud University Medical Center seem to have found an essential mechanism in the disease process of COVID-19, which has so far been overlooked.

29 Apr 2020

ACE2 News and Research

Study shows COVID-19 vulnerability is highly dependent on host genetic architecture

ACE inhibitors should not be discontinued over fears about COVID-19, say researchers

Repurposing existing drugs is a more rapid alternative than developing COVID-19 vaccine

Predicting the dose for repurposing nitazoxanide in COVID-19

Twist Bioscience Identifies Competitive Antibodies for SARS-CoV-2

Study discovers inhibition of SARS-CoV-2 entry priming protein by approved drug

Low CD8 and NK cell counts in the lung linked to high SARS-CoV-2 ACE2 receptor levels

Is ACEI, ARB use linked to testing positive for COVID-19?

SARS-CoV-2 genome shows mutation hotspots and type-specific distribution

COVID-19 infection risk and outcomes explained by the cell receptor genetic variability

Russian scientists create humanized mice to test drugs and vaccines for COVID-19

Loss of smell may be related to neuroinvasive propensity of SARS-CoV-2

SARS-CoV-2 receptor ‘mimic' could prevent COVID-19

Research detects a more dangerous SARS-CoV-2 mutation

High blood pressure drugs found to be safe for COVID-19 patients

Spike protein analysis from India's first SARS-CoV-2

New clinical trial to assess whether hypertension drug may reduce COVID-19 severity

New database catalogs peptides that may halt SARS-CoV-2 cell infection

Tobacco smoking identified as a potential risk factor for COVID-19 infection

Radboudumc researchers find essential mechanism in the disease process of COVID-19

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News